Innoviva (INVA) Stock Price, News & Analysis

Company Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Key Stats

• Today's Range: $17.89 to $18.33
• 50-Day Range: $18.17 to $21.80
• 52-Week Range: $16.67 to $22.00
• Volume: 675,247 shs
• Average Volume: 788,399 shs
• Market Capitalization: $1.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.33
• Consensus Rating: Buy

Innoviva Stock Analysis - MarketRank™

Innoviva scored higher than 87% of companies evaluated by MarketBeat, and ranked 292nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Innoviva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Innoviva has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 369.70%

Earnings Growth

Earnings for Innoviva are expected to grow by 369.70% in the coming year, from $0.33 to $1.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Innoviva is -18.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Innoviva is -18.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Innoviva has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.02% of the float of Innoviva has been sold short.

Short Interest Ratio / Days to Cover

Innoviva has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Innoviva has recently decreased by 2.93%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innoviva does not currently pay a dividend.

Dividend Growth

Innoviva does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.33

Percentage of Shares Shorted

16.02% of the float of Innoviva has been sold short.

Short Interest Ratio / Days to Cover

Innoviva has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Innoviva has recently decreased by 2.93%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.67

News Sentiment

Innoviva has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Innoviva this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innoviva insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.25% of the stock of Innoviva is held by insiders.

Percentage Held by Institutions

99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INVA Stock Analysis - Frequently Asked Questions

How have INVA shares performed this year?

Innoviva's stock was trading at $17.35 at the start of the year. Since then, INVA stock has increased by 5.2% and is now trading at $18.2470.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) announced its earnings results on Wednesday, August, 6th. The biotechnology company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.34. Innoviva had a positive trailing twelve-month return on equity of 15.77% and a negative net margin of 16.15%.

Who are Innoviva's major shareholders?

Top institutional shareholders of Innoviva include Denali Advisors LLC (0.53%), Allspring Global Investments Holdings LLC (0.47%), Hussman Strategic Advisors Inc. (0.33%) and Exchange Traded Concepts LLC (0.29%).
View institutional ownership trends.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

• Today: 8/06/2025
• Last Earnings: 8/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INVA
• Previous Symbol: NASDAQ:THRX
• CIK: 1080014
• Web: www.inva.com
• Phone: (650) 238-9600
• Fax: 650-827-8690
• Employees: 100
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Innoviva: $40.33
• High Price Target: $55.00
• Low Price Target: $26.00
• Potential Upside/Downside: +121.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 55.29
• P/E Growth: N/A
• Net Income: $23.39 million
• Net Margins: -16.15%
• Pretax Margin: -12.53%
• Return on Equity: 15.77%
• Return on Assets: 8.41%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 2.48
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $358.71 million
• Price / Sales: 3.19
• Cash Flow: $3.36 per share
• Price / Cash Flow: 5.43
• Book Value: $11.03 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 62,780,000
• Free Float: 61,363,000
• Market Cap: $1.15 billion
• Optionable: Optionable
• Beta: 0.38